Trends in mRNA Vaccine Development and Applications
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 106
Special Issue Editor
Interests: structure and non-target effects of mRNA-LNPs; anti-PEG antibodies; complement system/activation/inhibition; pharmacokinetics; immunotoxicity; adverse immunological side effects; hypersensitivity/allergic reactions; gene therapy; immune activation by nano-biopharmaceuticals; complement-activation-related pseudoallergy (CARPA);cytokine release/storm syndrome; in vitro/in vivo models of innate immune activation; infusion reactions/anaphylaxis; allergic/anaphylactic reactions to COVID vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since the roll-out of mRNA-lipid nanoparticle (LNP)-based COVID-19 vaccines in 2020, billions of people have been immunized with this type of vaccine, representing a novel technology platform to fight infectious diseases. Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax, the lead mRNA-LNP formulations, trigger immune responses that effectively reduce the pathogenicity of SARS-CoV-2, saving millions from severe illness or death. The mechanism of this benefit, details of these vaccines’ structure and function, as well as their side effects have been the subjects of unprecedented scientific and public attention, yet novelties in these fields emerge each day. Many believe that technology will surpass all other approaches of gene and pharmacotherapy, but there is also a lot of scientific and public discussion of presently ill-understood adverse effects, of which clarification is necessary to secure safe beside efficacy.
The goal of this Special Issue of Pharmaceutics is to provide a 2024 update on the most recent developments and prospects in this field, good or unfavorable, that may guide the development of next-generation mRNA-LNP vaccines and other pharmaceuticals. Original research data and comprehensive reviews are all welcome to be submitted to this Special Issue in order to make it a source of state-of-the-art information in the field.
Prof. Dr. Janos Szebeni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccines
- vaccination
- modified mRNA
- lipid nanoparticles (LNPs)
- mRNA-LNP
- COVID-19 pandemic
- SARS-CoV-2
- spike protein
- immunogenicity
- adverse reactions
